Additionally, as current preclinical models of AD are unable to recapitulate all aspects of AD pathogenesis, it is difficult to predict how overexpression of PADs upregulated in human AD might affect CARPs shown to be highly efficacious in animal models, such as RD2. This evidence concerns the gene PRPH2 and Alzheimer disease.